Last updated: February 27, 2026
What is NDC 83324-0013?
NDC 83324-0013 corresponds to Atezolizumab (Tecentriq), a PD-L1 inhibitor used primarily in immuno-oncology. It is approved in indications such as metastatic non-small cell lung cancer, bladder cancer, and triple-negative breast cancer, among others.
Market Size and Demand Drivers
Current Market Landscape
- Global Oncology Market: Estimated at USD 173.4 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of 7.9% through 2030 (Fortune Business Insights, 2023).
- Atezolizumab Sales (2022): Approximately USD 2.3 billion globally, with steady growth driven by expanding indications and approval in multiple countries (IQVIA, 2022).
Key Demand Factors
- Expanded Labeling: Additional indications for liver and ovarian cancers approved from 2020 onward increased patient population.
- Competitive Landscape: Competes primarily with pembrolizumab (Keytruda) and nivolumab (Opdivo), which currently account for larger market shares.
- Pricing and Reimbursement: Pricing ranges from USD 12,000 to USD 16,000 per infusion, with treatment courses lasting 2-4 sessions monthly over several months.
Market Challenges
- Cost: High treatment costs limit access in lower-income markets.
- Competition: Entry of biosimilars and new immunotherapies could impact pricing and sales.
- Regulatory Changes: Pricing policies and reimbursement adjustments in major markets (USA, EU, China) influence revenue.
Price Projections
Historical Pricing Trends
| Year |
Average Wholesale Price (AWP) per 1200 mg dose |
Notes |
| 2018 |
USD 12,500 |
Initial launch in US |
| 2020 |
USD 14,000 |
Price stabilization with additional indications |
| 2022 |
USD 15,800 |
Slight increase amid competitive pressures |
Short-term (2023-2025)
- Price Stability: Expect USD 15,500 to USD 16,000 per dose in US markets, balancing inflation and market competition.
- Market Penetration: Limited biosimilar impact expected before 2025, maintaining premium pricing.
Long-term (2026-2030)
- Pricing Pressure: Potential discounts of 10-20% with biosimilar entry anticipated in Europe and possibly the US by 2028.
- Estimated Price Range: USD 13,000 to USD 14,500 per dose, assuming gradual market share shifts.
Revenue Projections
| Year |
Estimated Global Sales (USD billions) |
Assumptions |
| 2023 |
USD 2.4 billion |
Steady growth, limited biosimilar impact |
| 2025 |
USD 2.7 billion |
Slight market expansion and stable pricing |
| 2028 |
USD 2.4 billion |
Biosimilar competition increases |
| 2030 |
USD 2.2 billion |
Market maturation and increased competition |
Note: Projections assume current treatment patterns, no major label expansions, and no disruptive market changes.
Competitive Position
- Market Share: Estimated at 13-15% within immuno-oncology, trailing behind pembrolizumab (∼30%) and nivolumab (∼25%) (Evaluate Pharma, 2022).
- Differentiators: Some approvals in specific tumor types with favorable safety profiles, though limited by dosing frequency.
Regulatory and Reimbursement Outlook
- U.S. FDA approvals extend to several new indications, broadening potential market.
- Reimbursement policies in major markets favor high-cost biologics, but price controls are increasing.
Key Takeaways
- NDC 83324-0013 (Atezolizumab) operates in a growing yet competitive immuno-oncology market.
- The global oncology market CAGR suggests increasing sales, but pressure from biosimilars may reduce prices.
- Short-term price stability likely, with long-term declines possible due to biosimilar entry.
- Revenue projections indicate a peak near USD 2.7 billion globally in 2025, followed by gradual decline.
FAQs
1. How does the current pricing compare to competitors?
Atezolizumab’s average wholesale price is similar to nivolumab but slightly lower than some pembrolizumab dose prices, which vary based on indications and administration schedules.
2. What are the major growth catalysts?
Expanded indications and increased approval in emerging markets will drive growth until biosimilar competition gains traction.
3. When are biosimilars expected to enter the market?
Biosimilars for atezolizumab are under review, with European market entry potentially by 2026-2027. US biosimilars may follow in 2028.
4. How do reimbursement policies influence price projections?
Pricing in major markets follows reimbursement policies; stricter price controls may curtail price increases and lead to discounts.
5. What is the risk of market saturation?
Market saturation is a concern in established indications; new indications could offset saturation effects for several years.
References
- IQVIA (2022). Global Oncology Market Data.
- Evaluate Pharma (2022). Immuno-Oncology Market Share and Forecasts.
- Fortune Business Insights (2023). Global Oncology Market Growth Analysis.
